INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
7.98
-0.26 (-3.16%)
Apr 24, 2025, 4:00 PM EDT - Market closed
INmune Bio Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for INmune Bio stock have an average target of 24.33, with a low estimate of 20 and a high estimate of 30. The average target predicts an increase of 204.89% from the current stock price of 7.98.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 13, 2025.
Analyst Ratings
The average analyst rating for INmune Bio stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +275.94% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +188.22% | Feb 11, 2025 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +150.63% | Oct 21, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $22 | Buy | Initiates | $22 | +175.69% | Aug 22, 2024 |
| Baird | Baird | Buy Initiates $16 | Buy | Initiates | $16 | +100.50% | Jun 1, 2023 |
Financial Forecast
Revenue This Year
n/a
from 14.00K
Revenue Next Year
5.52M
EPS This Year
-1.83
from -2.11
EPS Next Year
-1.74
from -1.83
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 15.2M | 25.5M | ||
| Avg | n/a | 5.5M | 15.9M | ||
| Low | n/a | n/a | 2.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 362.2% | ||
| Avg | - | - | 189.0% | ||
| Low | - | - | -53.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.66 | -1.18 | -0.83 | ||
| Avg | -1.83 | -1.74 | -1.32 | ||
| Low | -1.94 | -2.18 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.